Gregory M - Search Results

1

Role of bacterial and host factors in infectious endophthalmitis.

Gregory M, Callegan MC, Gilmore MS. Gregory M, et al. Chem Immunol Allergy. 2007;92:266-275. doi: 10.1159/000099277. Chem Immunol Allergy. 2007. PMID: 17264502 Review.

2

alphaB-crystallin protects retinal tissue during Staphylococcus aureus-induced endophthalmitis.

Whiston EA, Sugi N, Kamradt MC, Sack C, Heimer SR, Engelbert M, Wawrousek EF, Gilmore MS, Ksander BR, Gregory MS. Whiston EA, et al. Among authors: gregory ms. Infect Immun. 2008 Apr;76(4):1781-90. doi: 10.1128/IAI.01285-07. Epub 2008 Jan 28. Infect Immun. 2008. PMID: 18227158 Free PMC article.

3

Bacterial endophthalmitis: therapeutic challenges and host-pathogen interactions.

Callegan MC, Gilmore MS, Gregory M, Ramadan RT, Wiskur BJ, Moyer AL, Hunt JJ, Novosad BD. Callegan MC, et al. Among authors: gregory m. Prog Retin Eye Res. 2007 Mar;26(2):189-203. doi: 10.1016/j.preteyeres.2006.12.001. Epub 2007 Jan 22. Prog Retin Eye Res. 2007. PMID: 17236804 Free PMC article. Review.

4

Spontaneous bacterial keratitis in CD36 knockout mice.

Klocke J, Barcia RN, Heimer S, Cario E, Zieske J, Gilmore MS, Ksander BR, Gregory MS. Klocke J, et al. Invest Ophthalmol Vis Sci. 2011 Jan 5;52(1):256-63. doi: 10.1167/iovs.10-5566. Print 2011 Jan. Invest Ophthalmol Vis Sci. 2011. PMID: 20847111 Free PMC article.

5

Increased resistance to Staphylococcus aureus endophthalmitis in BALB/c mice: Fas ligand is required for resolution of inflammation but not for bacterial clearance.

Sugi N, Whiston EA, Ksander BR, Gregory MS. Sugi N, et al. Infect Immun. 2013 Jun;81(6):2217-25. doi: 10.1128/IAI.00405-12. Epub 2013 Apr 8. Infect Immun. 2013. PMID: 23569113 Free PMC article.

6

The Role of the Immune System in Glaucoma: Bridging the Divide Between Immune Mechanisms in Experimental Glaucoma and the Human Disease.

Kamat SS, Gregory MS, Pasquale LR. Kamat SS, et al. Semin Ophthalmol. 2016;31(1-2):147-54. doi: 10.3109/08820538.2015.1114858. Semin Ophthalmol. 2016. PMID: 26959140 Review.

7

Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.

Gregory MS, Repp AC, Holhbaum AM, Saff RR, Marshak-Rothstein A, Ksander BR. Gregory MS, et al. J Immunol. 2002 Sep 1;169(5):2727-35. doi: 10.4049/jimmunol.169.5.2727. J Immunol. 2002. PMID: 12193747

8

Control of ocular tumor growth and metastatic spread by soluble and membrane Fas ligand.

Gregory MS, Saff RR, Marshak-Rothstein A, Ksander BR. Gregory MS, et al. Cancer Res. 2007 Dec 15;67(24):11951-8. doi: 10.1158/0008-5472.CAN-07-0780. Cancer Res. 2007. PMID: 18089826

9

By altering ocular immune privilege, bone marrow-derived cells pathogenically contribute to DBA/2J pigmentary glaucoma.

Mo JS, Anderson MG, Gregory M, Smith RS, Savinova OV, Serreze DV, Ksander BR, Streilein JW, John SW. Mo JS, et al. Among authors: gregory m. J Exp Med. 2003 May 19;197(10):1335-44. doi: 10.1084/jem.20022041. J Exp Med. 2003. PMID: 12756269 Free PMC article.

10

A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.

Gregory MS, Koh S, Huang E, Saff RR, Marshak-Rothstein A, Mukai S, Ksander BR. Gregory MS, et al. Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2495-502. doi: 10.1167/iovs.05-0048. Invest Ophthalmol Vis Sci. 2005. PMID: 15980241

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

870 results

Search Page

Filters